Esperion Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Esperion Therapeutics' est Sheldon Koenig, nommé en May2021, a un mandat de 3.25 ans. La rémunération annuelle totale est $ 2.97M, composée du salaire de 24.3% et des bonus 75.7%, y compris les actions et options de la société. détient directement 0.084% des actions de la société, d'une valeur de $ 311.94K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.5 ans et 3 ans.

Informations clés

Sheldon Koenig

Directeur général

US$3.0m

Rémunération totale

Pourcentage du salaire du PDG	24.3%
Durée du mandat du directeur général	3.4yrs
Propriété du PDG	0.09%
Durée moyenne d'occupation des postes de direction	2.6yrs
Durée moyenne du mandat des membres du conseil d'administration	3.2yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Sheldon Koenig a-t-elle évolué par rapport aux bénéfices de Esperion Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$98m
Mar 31 2024	n/a	n/a	-US$87m
Dec 31 2023	US$3m	US$721k	-US$209m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$222m
Mar 31 2023	n/a	n/a	-US$239m
Dec 31 2022	US$4m	US$683k	-US$234m
Sep 30 2022	n/a	n/a	-US$243m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$8m	US$566k	-US$269m
Sep 30 2021	n/a	n/a	-US$308m
Jun 30 2021	n/a	n/a	-US$325m
Mar 31 2021	n/a	n/a	-US$156m
Dec 31 2020	US$508k	US$23k	-US$144m

Rémunération vs marché: La rémunération totale de Sheldon ($USD 2.97M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 992.88K ).

Rémunération et revenus: La rémunération de Sheldon a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Sheldon Koenig (58 yo)

3.4yrs

Titularisation

US$2,968,565

Compensation

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Sheldon Koenig	President	3.4yrs	US$2.97m	0.087% $ 359.6k
Eric Warren	Chief Commercial Officer	2.6yrs	US$1.08m	0.083% $ 341.4k
Benjamin Halladay	Chief Financial Officer	1.9yrs	pas de données	0.12% $ 512.2k
Glenn Brame	Chief Technical Operations Officer	1.8yrs	pas de données	pas de données
Benjamin Looker	General Counsel & Corporate Secretary	2.8yrs	US$1.29m	0.094% $ 385.7k
Tiffany Aldrich	Associate Director of Corporate Communications	no data	pas de données	pas de données
Betty Swartz	Chief Business Officer	no data	pas de données	pas de données

2.6yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0IIM est considérée comme expérimentée (ancienneté moyenne 2.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Sheldon Koenig	President	3.4yrs	US$2.97m	0.087% $ 359.6k
Nicole Vitullo	Lead Independent Director	16.5yrs	US$94.78k	0.016% $ 66.7k
Alan Fuhrman	Independent Non-Employee Director	4.6yrs	US$104.78k	0.027% $ 112.2k
Antonio Gotto	Independent Director	10.8yrs	US$82.28k	0.026% $ 108.4k
Jay Shepard	Independent Director	6.4yrs	US$97.28k	0.026% $ 108.4k
Stephen Rocamboli	Independent Director	2.5yrs	US$94.78k	0.018% $ 76.2k
J. Carroll	Independent Chairperson	2.3yrs	US$117.28k	0.033% $ 135.8k
Peter Libby	Member of Scientific Advisory Board	2.2yrs	pas de données	pas de données
Seth H. Fischer	Independent Director	3yrs	US$99.78k	0.014% $ 59.1k
Tracy Woody	Independent Director	5.4yrs	US$91.97k	0.014% $ 59.7k
Erin Bohula	Member of Scientific Advisory Board	2.2yrs	pas de données	pas de données
Jeffrey Bender	Member of Scientific Advisory Board	2.2yrs	pas de données	pas de données

3.2yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0IIM sont considérés comme expérimentés (ancienneté moyenne 3 ans).

Esperion Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

High number of new directors

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

Recent updates

Esperion Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Esperion Therapeutics, Inc. Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe)

Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.46 loss in 2Q 2023)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Esperion Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Full year 2023 earnings released: US$2.03 loss per share (vs US$3.52 loss in FY 2022)

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.81 loss in 3Q 2022)

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Forecast to breakeven in 2024

New major risk - Shareholder dilution

Forecast to breakeven in 2024

Second quarter 2023 earnings released: US$0.46 loss per share (vs US$1.05 loss in 2Q 2022)

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Forecast breakeven date moved forward to 2024

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.93 loss in 1Q 2022)

Full year 2022 earnings released: US$3.52 loss per share (vs US$9.31 loss in FY 2021)

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$2.62 loss in 3Q 2021)

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Second quarter 2022 earnings released: US$1.05 loss per share (vs US$1.67 loss in 2Q 2021)

High number of new directors

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

High number of new directors

First quarter 2022 earnings released: US$0.93 loss per share (vs US$3.50 loss in 1Q 2021)

High number of new directors

Esperion Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Esperion Therapeutics, Inc., Annual General Meeting, May 26, 2022

Esperion Therapeutics, Inc. Announces Appointment of Eric Warren, R.Ph. as Chief Commercial Officer

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Esperion Therapeutics, Inc. to Report Q4, 2021 Results on Feb 22, 2022

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Esperion Therapeutics, Inc. Provides Earnings Results for the Fourth Quarter of 2021

Third quarter 2021 earnings released: US$2.62 loss per share (vs US$3.07 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$1.67 loss per share (vs US$4.50 profit in 2Q 2020)

Robbins Geller Rudman & Dowd LLP and Kahn Swick & Foti, LLC Announces Proposed Settlement in the Esperion Therapeutics Securities Settlement

First quarter 2021 earnings released: US$3.50 loss per share (vs US$2.84 loss in 1Q 2020)

Esperion Announces Publication of Rationale and Design of Landmark Clear Cardiovascular Outcomes Trial Evaluating Nexletol (Bempedoic Acid) Tablet in American Heart Journal